Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis

Journal of Immunology

Volumn 188, Issue 12, 2012, Pages 6309-6318

  Schepp Berglind, Jennifer ^a   Atkinson, Carl ^a   Elvington, Michelle ^a   Qiao, Fei ^a   Mannon, Peter ^b   Tomlinson, Stephen ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b University of Alabama at Birmingham   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTIBIOTIC AGENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; DEXTRAN SULFATE; ENDOTOXIN; MANNOSE BINDING LECTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; COLITIS; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEFICIENCY; COMPLEMENT INHIBITION; COMPLEMENT LECTIN PATHWAY; CONTROLLED STUDY; DISEASE SEVERITY; HOST RESISTANCE; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TISSUE INJURY; WOUND HEALING;

ANIMALS; COLITIS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84862589661     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200553     Document Type: Article

References (31)

1. Ueki, T., M. Mizuno, T. Uesu, T. Kiso, J. Nasu, T. Inaba, Y. Kihara, Y. Matsuoka, H. Okada, T. Fujita, and T. Tsuji. 1996. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin. Exp. Immunol. 104: 286-292. (Pubitemid 26135444)
2. Halstensen, T. S., T. E. Mollnes, and P. Brandtzaeg. 1989. Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology 97: 10-19. (Pubitemid 19190990)
3. Halstensen, T. S., T. E. Mollnes, P. Garred, O. Fausa, and P. Brandtzaeg. 1992. Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut 33: 902-908.
4. Halstensen, T. S., T. E. Mollnes, O. Fausa, and P. Brandtzaeg. 1989. Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut 30: 361-366. (Pubitemid 19091163)
5. Halstensen, T. S., and P. Brandtzaeg. 1991. Local complement activation in inflammatory bowel disease. Immunol. Res. 10: 485-492.
6. Ahrenstedt, O., L. Knutson, B. Nilsson, K. Nilsson-Ekdahl, B. Odlind, and R. Hällgren. 1990. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N. Engl. J. Med. 322: 1345-1349. (Pubitemid 20154477)
7. Scheinin, T., T. Böhling, L. Halme, S. Kontiainen, L. Bjørge, and S. Meri. 1999. Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease. Hum. Pathol. 30: 1427-1430. (Pubitemid 30032917)
8. Berstad, A. E., and P. Brandtzaeg. 1998. Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut 42: 522-529. (Pubitemid 28186570)
9. Uesu, T., M. Mizuno, H. Inoue, J. Tomoda, and T. Tsuji. 1995. Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis. Lab. Invest. 72: 587-591.
10. Lin, F., D. Spencer, D. A. Hatala, A. D. Levine, and M. E. Medof. 2004. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J. Immunol. 172: 3836-3841. (Pubitemid 38337970)
11. Lu, F., S. M. Fernandes, and A. E. Davis, III. 2010. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 298: G878-G883.
12. Woodruff, T. M., T. V. Arumugam, I. A. Shiels, R. C. Reid, D. P. Fairlie, and S. M. Taylor. 2003. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J. Immunol. 171: 5514-5520. (Pubitemid 37432841)
13. Chen, G., Y. Yang, X. Gao, Y. Dou, H. Wang, G. Han, R. Wang, J. Wang, L. Wang, X. Li, et al. 2011. Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis. Lab. Invest. 91: 472-483.
14. Deguchi, Y., A. Andoh, O. Inatomi, Y. Araki, K. Hata, T. Tsujikawa, K. Kitoh, and Y. Fujiyama. 2005. Development of dextran sulfate sodium-induced colitis is aggravated in mice genetically deficient for complement C5. Int. J. Mol. Med. 16: 605-608.
15. Holers, V. M. 2008. The spectrum of complement alternative pathway-mediated diseases. Immunol. Rev. 223: 300-316. (Pubitemid 351986186)
16. Atkinson, C., H. Song, B. Lu, F. Qiao, T. A. Burns, V. M. Holers, G. C. Tsokos, and S. Tomlinson. 2005. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J. Clin. Invest. 115: 2444-2453. (Pubitemid 41266206)
17. Huang, Y., F. Qiao, C. Atkinson, V. M. Holers, and S. Tomlinson. 2008. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J. Immunol. 181: 8068-8076.
18. Song, H., C. He, C. Knaak, J. M. Guthridge, V. M. Holers, and S. Tomlinson. 2003. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J. Clin. Invest. 111: 1875-1885. (Pubitemid 38057732)
19. Peng, X. D., X. H. Wu, L. J. Chen, Z. L. Wang, X. H. Hu, L. F. Song, C. M. He, Y. F. Luo, Z. Z. Chen, K. Jin, et al. 2010. Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice. J. Pharmacol. Exp. Ther. 332: 46-56.
20. Matsuura, M., K. Okazaki, A. Nishio, H. Nakase, H. Tamaki, K. Uchida, T. Nishi, M. Asada, K. Kawasaki, T. Fukui, et al. 2005. Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology 128: 975-986. (Pubitemid 40523548)
21. Diaz-Granados, N., K. Howe, J. Lu, and D. M. McKay. 2000. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am. J. Pathol. 156: 2169-2177. (Pubitemid 30641783)
22. Prodeus, A. P., X. Zhou, M. Maurer, S. J. Galli, and M. C. Carroll. 1997. Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 390: 172-175. (Pubitemid 27507986)
23. Stahl, G. L., Y. Xu, L. Hao, M. Miller, J. A. Buras, M. Fung, and H. Zhao. 2003. Role for the alternative complement pathway in ischemia/reperfusion injury. Am. J. Pathol. 162: 449-455. (Pubitemid 36267852)
24. Hylton, D. J., S. M. Hoffman, N. Van Rooijen, S. Tomlinson, and S. D. Fleming. 2011. Macrophage-produced IL-12p70 mediates hemorrhage-induced damage in a complement-dependent manner. Shock 35: 134-140.
25. Johswich, K., M. Martin, J. Thalmann, C. Rheinheimer, P. N. Monk, and A. Klos. 2006. Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines. J. Biol. Chem. 281: 39088-39095. (Pubitemid 46041868)
26. Bak-Romaniszyn, L., A. Szala, A. Sokolowska, G. Mierzwa, M. Czerwionka- Szaflarska, A. S. Swierzko, K. Zeman, and M. Cedzynski. 2011. Mannanbinding lectin deficiency in pediatric patients with inflammatory bowel disease. Scand. J. Gastroenterol. 46: 1275-1278.
27. Hoffmann, C., P. Hoffmann, A. Lun, C. Büning, F. Hiepe, H. U. Scherer, E. Steinhagen-Thiessen, and A. Weimann. 2010. Is there a role for mannan-binding lectin in the diagnosis of inflammatory bowel disease? Immunogenetics 62: 231-235.
28. Rector, A., P. Lemey, W. Laffut, E. Keyaerts, F. Struyf, E. Wollants, S. Vermeire, P. Rutgeerts, and M. Van Ranst. 2001. Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn's disease. Genes Immun. 2: 323-328. (Pubitemid 33674244)
29. Müller, S., T. Schaffer, B. Flogerzi, B. Seibold-Schmid, J. Schnider, K. Takahashi, A. Darfeuille-Michaud, E. Vazeille, A. M. Schoepfer, and F. Seibold. 2010. Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens. Gut 59: 1493-1500.
30. Celik, I., C. Stover, M. Botto, S. Thiel, S. Tzima, D. Künkel, M. Walport, W. Lorenz, and W. Schwaeble. 2001. Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis. Infect. Immun. 69: 7304-7309. (Pubitemid 33086552)
31. Dahlke, K., C. D. Wrann, O. Sommerfeld, M. Sossdorf, P. Recknagel, S. Sachse, S. W. Winter, A. Klos, G. L. Stahl, Y. X. Ma, et al. 2011. Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis. J. Immunol. 186: 3066-3075.